HC Wainwright Issues Pessimistic Outlook for Curis Earnings

Curis, Inc. (NASDAQ:CRIS) – Equities research analysts at HC Wainwright decreased their Q2 2026 earnings estimates for shares of Curis in a research note issued on Wednesday, May 13th. HC Wainwright analyst S. Nik now forecasts that the biotechnology company will post earnings of ($0.29) per share for the quarter, down from their previous estimate of ($0.21). HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Curis’ current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Curis’ Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.30) EPS and FY2026 earnings at ($0.91) EPS.

Other analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curis in a research report on Monday, April 20th. Wall Street Zen raised Curis to a “hold” rating in a report on Saturday, March 28th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $17.00.

Curis Price Performance

Shares of CRIS opened at $0.51 on Friday. The company’s fifty day moving average price is $0.67 and its 200-day moving average price is $0.97. Curis has a 1-year low of $0.49 and a 1-year high of $3.13. The firm has a market capitalization of $20.52 million, a PE ratio of -0.43 and a beta of 3.08.

Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.92).

Institutional Trading of Curis

A number of hedge funds and other institutional investors have recently made changes to their positions in CRIS. Jane Street Group LLC raised its holdings in shares of Curis by 71.8% during the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 10,586 shares during the last quarter. XTX Topco Ltd acquired a new stake in Curis during the 4th quarter worth about $26,000. Warberg Asset Management LLC acquired a new stake in Curis during the 3rd quarter worth about $73,000. Squarepoint Ops LLC raised its stake in shares of Curis by 17.9% during the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 8,973 shares during the last quarter. Finally, Focused Wealth Management Inc raised its stake in shares of Curis by 83.4% during the 1st quarter. Focused Wealth Management Inc now owns 109,746 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 49,900 shares during the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.